The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nedaplatin plus pemetrexed or cisplatin plus pemetrexed as first-line chemotherapy for EGFR/ALK-negative advanced lung adenocarcinoma (NACA): A multicenter, open-label, non-inferiority, randomized, phase III trial.
 
Xue Hou
No Relationships to Disclose
 
Weineng Feng
No Relationships to Disclose
 
Hao Long
No Relationships to Disclose
 
Qing Bu
No Relationships to Disclose
 
Chengzhi Zhou
No Relationships to Disclose
 
Huafeng LIU
No Relationships to Disclose
 
Chao CHENG
No Relationships to Disclose
 
Lin WANG
No Relationships to Disclose
 
Guowu Wu
No Relationships to Disclose
 
Shimin Wen
No Relationships to Disclose
 
Tong Zhou
No Relationships to Disclose
 
Xicheng Wang
No Relationships to Disclose
 
Dongying LIU
No Relationships to Disclose
 
Xiaoxia Bi
No Relationships to Disclose
 
Encun Hou
No Relationships to Disclose
 
Hua Jiang
No Relationships to Disclose
 
Likun Chen
No Relationships to Disclose